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Abstract The majority of first-time angiography patients
are without obstructive coronary artery disease (CAD). A
blood gene expression score (GES) for obstructive CAD
likelihood was validated in the PREDICT study, but its
relation to major adverse cardiovascular events (MACE)
and revascularization was not assessed. Patients (N01,160)
were followed up for MACE and revascularization 1 year
post-index angiography and GES, with 1,116 completing
follow-up. The 30-day event rate was 23% and a further
2.2% at 12 months. The GES was associated with MACE/
revascularizations(p<0.001)and added toclinicalriskscores.
Patients with GES >15 trended towards increased >30 days
MACE/revascularization likelihood (odds ratio02.59, 95%
confidence interval00.89–9.14, p00.082). MACE incidence
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DOI 10.1007/s12265-012-9353-zoverall was 1.5% (17 of 1,116) and 3 of 17 patients had
GES ≤15. For the total low GES group (N0396), negative
predictive value was 90% for MACE/revascularization
and >99% for MACE alone, identifying a group of patients
without obstructive CAD and highlyunlikelytosufferMACE
within 12 months.
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GES Gene expression score
CAD Coronary artery disease
MACE Major adverse cardiovascular events
NPV Negative predictive value
MI Myocardial infarction
QCA Quantitative coronary angiography
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PCI Percutaneous coronary intervention
CABG Coronary artery bypass graft
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Introduction
Chronic coronary artery disease (CAD) and adverse cardio-
vascular events are the largest sources of morbidity and
mortality in the developed world and are diagnosed in more
than 500,000 new patients annually in the USA [1]. Ob-
structive CAD diagnosis is challenging as patient presenta-
tion may often be variable and atypical symptoms are
common [2]. Clinical evaluation of suspected CAD often
includes stress testing followed by noninvasive imaging
(stress echocardiography or nuclear perfusion) and, if indi-
cated, invasive coronary angiography. Recent studies have
highlighted the relatively high radiation exposure burden in
the standard CAD workup [3, 4] and have indicated that, for
patients without a prior CAD diagnosis, <40% have obstruc-
tive CAD when referred for coronary angiography [5]. In
addition, the COURAGE trial suggested that optimal med-
ical therapy was noninferior to percutaneous coronary inter-
vention (PCI) for hard cardiovascular endpoints in patient
populations with stable angina and CAD [6]. Thus, nonin-
vasive genomic-based methods for CAD diagnosis may
have significant clinical utility and lead to lower diagnostic
costs in these patient populations.
We described differential blood cell gene expression lev-
els in patients with CAD [7] and, more recently, the devel-
opment and clinical validation in the PREDICT study of a
gene expression score (GES) comprised of the expression
levels of 23 genes, age, and sex [8, 9]. In this angiographic
population of nondiabetic patients, approximately 80% were
symptomatic and the quantitative coronary angiography
(QCA)-defined obstructive CAD prevalence was 36%; the
GES negative predictive value (NPV) was 83% at a score
threshold of 15, with 33% of patients below this threshold.
Furthermore, the GES correlated with QCA-determined
maximum percent stenosis. Toevaluatetheoutcomesofthese
GES patients, we monitored 1,160 PREDICT patients for
major adverse cardiovascular events (MACE) and interven-
tional procedures for 12 months from index catheterization.
Methods
General Study Design and Study Population
Subjects were enrolled in PREDICT, a 39-center prospec-
tive study, between July 2007 and April 2009 (http://www.
clinicaltrials.gov, NCT 00500617). The study complied with
the Declaration of Helsinki, was approved by institutional
review boards at all centers, and all patients gave written
informed consent. Subjects referred for diagnostic coronary
angiography were eligible with a history of chest pain,
suspected angina equivalent symptoms, or a high risk of
CAD and no known prior myocardial infarction (MI), re-
vascularization, or obstructive CAD. Subjects were ineligi-
ble if at catheterization they had acute MI, high-risk unstable
angina, severe noncoronary heart disease (congestive heart
failure, cardiomyopathy, or valve disease), systemic infec-
tious or inflammatory conditions, or were taking immuno-
suppressive or chemotherapeutic agents. Detailed eligibility
criteria have been described [9].
From 1,354 enrolled nondiabetic subjects who met the
inclusion criteria, 5 had angiographic images unsuitable for
QCA and 6 had unusable blood samples. The remaining
1,343 were divided into independent algorithm development
and validation cohorts sequentially based on enrollment [9];
of these, 1,166 patients had valid GES, 640 in algorithm
development and 526 in validation [9]. Thesewereevaluated
for events, with six subjects from algorithm development not
meeting the clinical inclusion criteria upon further evaluation.
Clinical Evaluation and Quantitative Coronary Angiography
Prespecified clinical data, including demographics, medica-
tions, clinical history, and presentation, were obtained by
research study coordinators using standardized data collec-
tion methods and verified by independent study monitors.
Coronary angiograms were analyzed by computer-
assisted QCA. Specifically, clinically indicated coronary
angiograms performed according to site protocols were dig-
itized, deidentified, and analyzed with a validated quantita-
tive protocol at the Cardiovascular Research Foundation,
New York, NY, USA [10]. All lesions >10% diameter
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ally identified, and the minimal lumen diameter (MLD),
reference lumen diameter (RLD0average diameter of nor-
mal segments proximal and distal of lesion), and %DS (%
DS0(1−MLD/RLD)×100) were calculated.
The Diamond–Forrester (D-F) risk score, comprised of
age, sex, and chest pain type, was prospectively chosen to
evaluate the value of the GES with clinical factors [11]. D-F
classifications of chest pain type (typical angina, atypical
angina, and nonanginal chest pain) were assessed using
subject interviews [11] and D-F scores assigned [12].
Obstructive CAD and Disease Group Definitions
Obstructive CAD (N0422) was defined prospectively as ≥1
atherosclerotic plaque in a major coronary artery (≥1.5 mm
lumen diameter) causing ≥50% luminal DS by QCA; non-
obstructive CAD (N0744) had no lesions >50%.
Clinical Procedure and Event Determination
Clinical interventions were defined as any PCI or coronary
artery bypass graft (CABG). Clinical events were defined as
stroke/transient ischemia attack (TIA), MI, or death. Index
coronary angiography was defined as the date of planned
coronary catheterization, irrespective of intervention. Coro-
nary procedures or events occurring within 30 days of index
angiography were considered baseline endpoints associated
with this procedure. In addition, specifically identified
staged procedures up to 45 days post-index angiography
were also considered baseline endpoints. Analysis of all
procedures and events was performed for the 1,160 subjects
over the entire follow-up period, as well as selective analysis
for patients with procedures and events beyond the 30-day
threshold.
All coronary procedures and events were monitored
against medical records for accuracy and were supported
by medical records documenting the specific event or diag-
nosis and/or by supporting evidence, e.g., myocardial en-
zyme elevation or infarct on head computed tomography
(CT). Discrepancies were resolved by direct investigator
query. All other events such as aortic aneurysm repair,
congestive heart failure exacerbation, and cardiac arrhyth-
mias were reviewed and eliminated due to noncardiac origin
or lack of direct association with acute coronary atheroscle-
rosis etiology. The definitions of the MACE components,
MI, stroke/TIA, and all-cause mortality are detailed in the
Supplementary Methods.
GES Measurements
GES measurements were performed in the CardioDx clini-
cal reference laboratory (Palo Alto, CA, USA) using the
Corus™ CAD process [9]. Briefly, RNAwas purified using
an automated bead-based method from PAXgene® RNA
preservation tubes (PreAnalytiX, Valencia, CA, USA). Sub-
sequent cDNA synthesis and reverse transcription polymer-
ase chain reaction were then carried out [9]. The GES were
reported on a 1–40 scale.
Statistical Analysis
The primary endpoint for the study was whether the GES
as a continuous variable was significantly related to the
combination of procedures and MACE at 30 days and
12 months following index angiography. Subjects were
censored if no event occurred prior to them being lost to
follow-up. Only the first endpoint of a given type (proce-
dure or event) was counted in the analysis. Secondary
analyses included the relationship of the GES to MACE
across the entire follow-up period and to the combination
of revascularizations and MACE occurring >30 post-index
catheterization.
For categorical analyses, the GES were divided into three
ranges: 1–15 (<20% likelihood), 16–27 (≥20–<50% likeli-
hood), and 28–40 (≥50% likelihood) [9]. Logistic regression
was used to test the relation between the GES (continuous)
and events/procedures; for comparison to clinical factor
scores, multivariate logistic regression was used. Odds ra-
tios (OR), associated 95% confidence intervals (95% CI),
and p values were also estimated by logistic regression. A
prespecified GES threshold of ≤15 was used to estimate test
performance (sensitivity, specificity, NPV, and positive pre-
dictive value [PPV]), as well as for categorical GES OR
analyses. The Cochran–Armitage trend test was used to test
the relation between GES categories and events/procedures.
Clinical factors were compared at baseline using either a
two-sample t test (continuous measures) or Fisher’s exact test
(binary measures). All analyses were performed in R version
2.11 [13].
Results
From 1,166 sequential PREDICT patients comprising the
algorithm development and clinical validation cohorts with
QCA and GES [9], 1,160 were eligible for follow-up and
1,116 (96%) were followed up for 1 year after index angi-
ography. Clinical and angiographic characteristics of this
entire cohort and the clinical validation subset (N0526)
are shown in Table 1. The entire cohort was 58% male with
an average age of 60. Factors which were significantly (p<
0.001) associated with angiographically defined obstructive
CAD at baseline included male sex, age, systolic blood
pressure (SBP), dyslipidemia, smoking status, chest pain
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and beta-blocker use (Table 1). Only 36% of patients had
obstructive CAD (≥50% maximum percent stenosis) at index
angiography.
The patient study flow is shown schematically in Fig. 1.
A total of 267 patients (23%) had endpoints within 30 days
of index procedure with the vast majority being PCI or
CABG. After censoring these patients, there were only 25
additional patients (3%) with procedures or events in the
next year out of the remaining 850, yielding an overall
endpoint rate of 25% for all patients in the entire period.
For MACE alone, the rate was 1.5% for 12 months. Events
and procedures are summarized in Table 2.
Table 1 Clinical and demographic characteristics of PREDICT patient
cohorts
Set parameter Complete cohort Clinical validation
subset
N 1,160 526
Male sex 668 (57.6%) 299 (56.8%)
Age 59.9±11.8
(25.5 to 90.9)
60.3±11.6
(25.6 to 90.9)
SBP 134.9±18.3 (88 to
213)
135.2±18.4 (90 to
213)
Dyslipidemia 734 (63.3%) 341 (64.8%)
Smoker 412 (35.5%) 186 (35.4%)
Symptomatic 762 (65.7%) 359 (68.3%)
BMI 30.8±6.8
(13.8 to 69.4)
30.7±6.5
(13.8 to 61.7)
Aspirin use 768 (66.5%) 363 (69.1%)
Statin use 580 (50.2%) 265 (50.5%)
Beta-blocker use 425 (36.8%) 212 (40.4%)
QCAMaxStenosis
a 38.2±32.3 (0 to 100) 38.9±32.1 (0 to 100)
QCANumLesions
b 1.8±2.3 (0 to 12) 1.9±2.4 (0 to 10)
QCAObsDisease
c 420 (36.2%) 192 (36.5%)
One-year follow-
up
1,115 (96.1%) 507 (96.4%)
aMaximum percent stenosis determined by core laboratory QCA
bNumber of ≥30% stenotic lesions by QCA
cPatients with ≥50% stenosis in a major coronary artery by QCA
Fig. 1 Schematic of patient
flow and endpoint summary. A
total of 1,166 patients from the
algorithm development and
validation cohorts were followed
up. There were 6 late clinical
exclusions, resulting in a final
cohort of 1,160 of whom follow-
up data was available for 1,143
(96%). A total of 267 had inter-
v e n t i o n a lp r o c e d u r e so re v e n t s
associated with their index
angiographic procedure (within
30 days). The remaining 850
patients had a total of 25 end-
points (14 interventional proce-
dures and 11 adverse events) in
the subsequent follow-up period,
for a total of 292 endpoints
(25%) over 1 year
Table 2 Summary of procedures and events at 1-year follow-up
Parameter
N at index angiogram 1,160
Baseline procedures
PCI 203 (17.5%)
CABG 70 (6%)
Total procedures
a 267 (23%)
Baseline events 6 (0.5%)
All baseline endpoints 267 (23%)
N with follow-up 1,116 (96%)
Follow-up procedures 14 (1.2%)
Follow-up events 11 (0.9%)
Total follow-up endpoints 25 (2.2%)
All procedures 286 (24.7%)
All events 17 (1.5%)
All endpoints
b 292 (25.2%)
aSome patients had more than one procedure and four patients had
events after baseline procedures
bThe total baseline number of patients is used as the denominator for
all calculations as baseline endpoints greatly dominate total endpoints.
Some patients had more than one endpoint
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The GES, comprised of the peripheral blood cell expression
levels of 23 genes and sex-specific age dependencies of
CAD likelihood, was associated with the composite primary
endpoint of MACE and procedures over 1 year by logistic
regression (p<0.001) and added to clinical factors, as quan-
tified by D-F or Framingham risk scores (Supplementary
Table 1). GES category also correlated with the likelihood
of the combined procedures and MACE primary endpoint
over this period as shown in Fig. 2a.
Previous analysis of obstructive CAD in the PRE-
DICT clinical validation study identified a low likeli-
hood (<20%) group with GES ≤15 [9]. Using this
threshold for the primary composite endpoint at 12 months
follow-up, the sensitivity and specificity were 86% and 41%,
respectively, corresponding to the NPV of 90% and PPV of
33%, with 396 patients (35%) in this group (Table 3). The OR
for those with nonlow scores (>15) versus low scores (≤15)
for the 30-day and 12-month endpoints were 4.3 (95% CI,
3.0–6.4) and 4.3 (95% CI, 3.0–6.3), respectively, both p<
0.001 (Table 3).
There were 17 patients with MACE, of which 15 oc-
curred more than 30 days after index angiogram; 4 of these
patients had early revascularization. The clinical, angio-
graphic, and MACE characteristics for all patient events
are summarized in Table 4. The GES at index procedure
was above 15 in 14 of 17 of these patients (Table 4, Fig. 2b).
Thus, at most, 3 patients of 1,160 (0.3%) had both a low
GES and an adverse event in the following year, yielding an
NPV for events alone of 99.2%, although this did not reach
statistical significance (OR02.41, 95% CI00.74–10.4, p0
0.16). There were a total of eight patients with late revascu-
larizations whose characteristics are summarized in Table 5,
with seven of eight having GES above 15. Patients with
either late revascularizations or MACE more than 30 days
post-index catheterization trended towards higher GES (OR0
2.59, 95% CI, 0.89–9.14, p00.082) (Table 3); the relationship
between the GES and these late revascularizations and events
are illustrated in Fig. 2b.
Discussion
Thisstudyextendedourpreviousvalidationofablood-based
GES for obstructive CAD in nondiabetic patients from an
angiographic endpoint to revascularizations and MACE. We
followed up and identified revascularizations and adverse
events in 1,160 patients from the PREDICT trial, including
the previously defined validation cohort of 526 patients for
12 months from index procedure. As expected, revasculari-
zation (PCI and CABG) were closely associated with max-
imum percent stenosis and angiographically determined
disease burden, with the exception of chronic total occlu-
sions which had a reduced intervention rate.
Our previous analysis showed that, in the validation set
of 526 patients, using obstructive CAD as the endpoint,
33% of patients had GES ≤15 with an NPV of 83%. For
actual clinical endpoints up to 1 year, the NPV for all
procedures and MACE was 90% at this threshold in the
Fig. 2 a Dependence of event and interventional procedure likelihood
on GES in 1 year. The percentage of patients who had interventional
procedures or events within 1 year of the index catheterization are
shown stratified by GES. GES are divided into low (1–15), medium
(16–27), and high (28–40) categories as described in the text. Results
are shown for the entire cohort of 1,160 patients. b Dependence of
MACE likelihood on GES in 1 year. The percentage of patients
who had MACE within 1 year of index catheterization are shown
stratified by GES (striped bars). The percentage of patients with
revascularization or MACE >30 days post-index catheterization are
shown stratified by GES (solid bars). Scores are divided as in a.T h e r e
were 3, 9, and 5 events for MACE alone (striped bars) and 4, 11, and 4
revascularizations and MACE (solid bars) in the low, medium, and high
GES categories
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1,160), representing 35% of total enrollment, only 41 of
1,160 (3.5%) had procedures or events. In these patients,
the majority of endpoints (28 of 41) were PCI which has not
been shown to improve long-term outcomes over optimal
medical therapy in the COURAGE population [6].
It has been demonstrated that the fraction of obstructive
CAD at cardiac catheterization in US patients without
known CAD is 35–40% [5, 9]. In the entire cohort in this
study, the yield of obstructive CAD was 36.2% and the
fraction of patients with interventions was 23.7%. If one
did not send patients with low GES for catheterization, the
yield of patients with obstructive CAD and interventions
would be increased to 48.2% and 31%, respectively.
We previously observed that increasing GES correlated
with maximum percent stenosis. In the current analysis, the
composite endpoint likelihood also monotonically increased
with GES from approximately 10% for low scores to >35%
with high scores (28–40) with an OR of >4 (Fig. 2a). For
high scores, this was likely an underestimate as >80% of
Table 3 Dependence of combined procedure and MACE risk on GES
Duration and endpoints NPV
a (%) PPV (%) Sensitivity (%) Specificity (%) OR
b 95% CI P value
12-month procedures and MACE
c 90 33 86 41 4.32 3.02–6.25 <0.001
12-month MACE 99 1.8 82 34 2.41 0.74–10.5 0.16
d
≤30-day procedures and MACE
e 91 33 87 40 4.31 3.00–6.38 <0.001
>30-day procedures and MACE 99 3.0 79 41 2.59 0.89–9.14 0.082
e
aNPV, PPV, sensitivity, and specificity were calculated at a threshold of 15
bOR were calculated with a GES threshold of 15
cProcedures (PCI or CABG) and MACE (MI, stroke/TIA, death) within 12 months of the index angiography
dNot significant
eProcedures and MACE occurring within 30 days of the index angiography
Table 4 Clinical characteristics of patients with subsequent events
Patient ID Sex Age
(years)
QCACase:
Control
a
QCAMax
Stenosis
ClinMax
Stenosis
QCANum
Lesions30
b
GES Event Days post
index
C002:00400185 Male 83 Control 0 15 0 31 Stroke or TIA 328
C003:00400346 Female 58 Case 70 0 1 10 MI
c 121
C004:00400011 Female 73 Control 39 50 1 17 MI 259
C005:00400009 Male 50 Case 100 100 1 18 CABG, MI, PCI 10
C014:00400055 Male 60 Case 76 90 5 29 Stroke or TIA 566
d
C015:00400040 Male 51 Case 57 40 3 24 Stroke or TIA >180
d
C015:00400058 Female 46 Control 0 0 0 2 MI
e 339
C015:00400064 Male 66 Control 15 80 0 25 Stroke or TIA 321
C015:00400092 Male 49 Control 19 30 0 25 MI >180
f
C015:00400193 Female 66 Case 78 70 6 16 MI 129
C051:00400030 Male 63 Case 75 90 6 26 MI 1
C058:00400054 Male 69 Control 33 40 2 25 Death >180
f
C063:00400007 Female 76 Case 80 90 5 27 MI 177
d
C068:00400065 Male 86 Case 81 95 1 37 Stroke or TIA 235
d
C073:00400040 Male 73 Control 44 65 1 30 Stroke or TIA 172
d
C073:00400065 Male 60 Case 63 40 3 14 MI 224
C079:00400014 Male 78 Case 100 50 7 39 Death 306
aProspectively defined as ≥50% maximum stenosis
bNumber of lesions >30% stenosis by QCA
cDiscrepancy between clinical and core laboratory QCA reads; QCA confirmed on subsequent independent review
dThese patients had a revascularization associated with their index catheterization
eLikely vasospastic MI given underlying clinical condition and chart review
fEvent reported at 1 year follow-up without specific date
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not intervened on, had high scores. A large recent study of
patients referred for CT angiography has also shown that
overall mortality risk correlated with the extent of maximum
percent stenosis [14].
For the small number of patients who had events, >80%
(14 of 17) had GES above the threshold of 15 (Tables 3 and
4), although this did not reach statistical significance. Ret-
rospective analysis for the three patients with events and low
GES showed one patient had no CAD angiographically with
a GES of 2 and likely suffered a vasospastic MI. A second
patient had no CAD by clinical angiogram, but subsequent
QCA showed a 70% lesion. The third patient had a score of
14, close to the threshold, and an MI 7 months from index
procedure. Thus, based upon clinical workup, 16 of 17
patients with events had scores above the threshold. Simi-
larly, for late revascularizations, seven of eight had scores
above 15.
A description of the genes which comprise the GES are
shown in Table 6, along with the associated biological
functions, where known. The predominant features of these
gene terms are the innate immune response, as judged by
increased expression of activation genes in both neutrophils
and natural killer (NK) cells, as well as an increase in
proapoptotic genes (terms 1–3). In addition, term 2, and
specifically S100A12, has been shown to promote coronary
artery calcification in a transgenic model [15]. In addition,
the somewhat counterintuitive B cell to T cell ratio com-
prises term 4. Although it was originally thought that B cells
were atheroprotective and T cells atherogenic, recent work
in mouse models has suggested a more complex picture with
atherogenic B cell subsets [16] and a potential atheropro-
tective role for regulatory T cells [17, 18].
Given that the GES was derived to discriminate ob-
structive CAD, why might it have prognostic value?
First, the GES is proportional to maximum percent
stenosis by angiography and a recent large CT angiog-
raphy study has shown that event likelihood increases
with the extent of disease, even for nonobstructive dis-
ease [19]. Second, specific terms in the GES algorithm
Table 5 Clinical characteristics of patients with late revascularizations
Patient ID Sex Age
(years)
QCACase:
Control
a
QCAMax
Stenosis
ClinMax
Stenosis
QCANum
Lesions30
b
GES Procedure
c Days post
index
C015:00400017 Male 54.4 Case 60.37 70 3 26 PCI 341
C054:00400009 Female 70.3 Case 100 80 3 25 CABG 75
C015:00400060 Male 55.5 Control 36.43 100 3 23 PCI 118
C055:00400036 Female 68.3 Control 24.2 40 0 20 PCI 345
C068:00400058 Female 55.2 Case 100 99 8 3 PCI 347
C001:00400105 Male 73.7 Case 60.7 90 2 32 PCI 70
C015:00400177 Male 64.5 Control 43.19 50 2 26 PCI 246
C068:00400087 Male 68.1 Case 100 100 5 37 CABG 84
aProspectively defined as ≥50% maximum stenosis
bNumber of lesions >30% stenosis by QCA
cEither PCI or CABG occurring without prior intervention associated with index catheterization
Table 6 GES components and
putative biological roles Term Genes Functions
1 IL18RAP+TNFAIP6+CASP5 Innate immunity, apoptosis
IL8RB+KCNE3+TLR4+TNFRSF10C Neutrophil activation
2 S100A8+S100A12+CLEC4E Neutrophil activation and necrosis
RPL28 (men), NCF4+AQP9 (women) Calcification
Neutrophil/lymphocyte ratio (men)
Normalized neutrophil activation (women)
3 SLAMF7+KLRC4 Innate immunity, NK cell activation
TMC8+CD3D Normalized to T lymphocytes
4 SPIB+CD79B B/T cell ratio
TMC8+CD3D Lymphocyte subtype
5+6 AF289562+TSPAN16 (men) Unknown function genes
TFCP2+HNRPF
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the case of the neutrophil to lymphocyte ratio has been
shown to have prognostic significance in a large cathe-
terization laboratory population [20]. In addition, a very
recent large study has shown that neutrophil counts
alone are associated with subsequent MI and mortality
[21]. Third, circulating levels of the protein products of
genes which are present in the GES, such as S100A8
and S100A12, have been shown to be associated with
cardiovascular events [22, 23]. Finally, the observed
GES proportionality to disease burden is most likely a
reflection of the dysregulation of gene expression in the
circulating cells in response to both the extent and
inflammatory activity of atherosclerotic plaque, perhaps
reflecting plaque composition.
This study had several limitations. First, the population
was nondiabetic and largely symptomatic with high-risk
unstable angina and low-risk asymptomatic patients exclud-
ed. Second, the follow-up period was limited and the num-
ber of events subsequent to the index catheterization small.
Thus, any conclusions about the PPVof the GES for prog-
nosis will require larger cohorts, more extended follow-up,
and a higher absolute number of cumulative events. Given
the observed OR for MACE in this study, we estimate that a
study of 2,300 patients with 2-year follow-up would have
80% power to detect a significant relationship of the GES to
MACE. The PROMISE study (http://www.clinicaltrials.gov,
NCT 01174550) might be an appropriate setting to further
test this hypothesis. Third, we did not have lesion-specific
information to determine if revascularizations or events
were due to baseline-identified lesions or disease progres-
sion. Fourth, since this was an angiographic population, it
had more disease than an intended use population before
referral, which may affect the results. Fifth, with respect to the
GESanalysis,thecombinedcohortmayhavebeen biased by
inclusion of the algorithm development set. This seems
unlikely to be a very significant factor as procedures and
events were not used to derive the algorithm, and the
validation subset analyses showed results indistinguish-
able from the entire population. Finally, while the GES
added significantly to Framingham with respect to the
primary composite endpoint, it did not add significantly
to MACE prediction alone, although that comparison
was underpowered due to the low event rate.
In summary, this study examined the relationship be-
tween a peripheral blood GES measured at index angiogra-
phy and revascularization and MACE at up to 12 months.
Independent of the GES, more than 75% of patients had
neither a procedure nor MACE in the next year. For those
with low GES, representing 35% of patients, 90% were in
this category. Thus, low GES appeared to identify a popu-
lation at low risk for both obstructive CAD and subsequent
procedures or events. While these results were encouraging
for a clinical correlation with the initial angiographic
validation, studies in larger populations with longer-term
follow-up would be needed to further support this
hypothesis.
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